Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics (Nasdaq: ENLV) announced a $15 million registered direct offering with a healthcare-focused institutional investor.
The deal includes $5 million upfront for 3,571,429 ordinary shares at $1.40 per share and associated clinical milestone-linked warrants. The Series A warrants expire 18 months after issuance or 60 days post-publication of positive topline results from the ENX-CL-05-001 trial for Allocetra in knee osteoarthritis. Series B warrants expire 5.5 years after issuance or 60 days post-FDA filing for Allocetra's osteoarthritis indication.
Gross proceeds could total $10 million if all warrants are exercised. The offering closes around May 29, 2024, with H.C. Wainwright & Co. as the placement agent.
- Up to $15 million in gross proceeds.
- Initial $5 million investment secured.
- Potential additional $10 million if warrants are fully exercised.
- Designed to support working capital and general corporate purposes.
- Partnership with healthcare-focused institutional investor.
- Potential for shareholder dilution with the issuance of 3,571,429 shares and additional warrants.
- No assurance that warrants will be exercised, making additional $10 million uncertain.
- Series A and Series B warrants tied to successful clinical milestones, adding execution risk.
Insights
The recent direct offering from Enlivex Therapeutics Ltd. stands to inject up to
The exercise conditions tied to the warrants – linked directly to the company’s clinical progress with AllocetraTM – suggest that the management is confident in their upcoming trial results and their ability to secure FDA approval. If these milestones are not met, the additional funds may not materialize, which could hinder the company's longer-term financial stability.
For retail investors, it’s important to note that while the upfront
The direct link of the Series A and Series B warrants to clinical milestones for AllocetraTM in treating moderate-to-severe knee osteoarthritis reflects Enlivex Therapeutics' strategic focus on advancing their pivotal trials. This form of funding demonstrates a commitment to achieving specific clinical outcomes, which could be very promising if successful. It incentivizes the company to reach these important milestones expediently, aligning investor interests with clinical progress.
From a medical perspective, reaching these milestones will not only provide financial benefits but also validate Enlivex’s scientific approach and innovation in macrophage reprogramming immunotherapy. The success of the ENX-CL-05-001 trial and subsequent FDA filings would be a significant step forward, potentially opening up new therapeutic avenues and enhancing the company’s credibility in the biopharmaceutical sector.
However, the inherent risks associated with clinical trials cannot be ignored. The linked warrants' value heavily relies on positive trial outcomes and regulatory approvals, which are not guaranteed. Investors should be prepared for the binary nature of biopharmaceutical investments, where success can lead to substantial rewards and failure can result in significant losses.
- Single healthcare-focused institutional investor
$5 million upfront with up to an additional$10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants
Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of
The warrants will have an exercise price of
The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form F-3 (File No. 333-264561), including a base prospectus, that was originally filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2022, and declared effective by the SEC on May 5, 2022. The offering of such securities in the registered direct offering is being made only by means of a prospectus supplement that forms a part of such effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained, when available, from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein or any other securities, nor shall there be any sale of the securities described herein or any other securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Enlivex
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions. For more information, visit https://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "could," "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including market and other conditions; the ability of the Company to satisfy all conditions precedent to the closing of the offering; the completion of the offering; the ability of the Company to achieve certain milestone events; the exercise of the warrants upon the achievement of such milestone events or otherwise prior to their expiration; the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
FAQ
What is the total potential funding from Enlivex Therapeutics' registered direct offering?
What is the purchase price per share in the Enlivex Therapeutics' direct offering?
When is the expected closing date for Enlivex Therapeutics' direct offering?
What is the ticker symbol for Enlivex Therapeutics?
What are the expiration terms for the Series A and Series B warrants in Enlivex Therapeutics' offering?
